Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Latest CDEX Press Releases.......
http://www.cdex-inc.com/pr.html
PRESS RELEASES
•CDEX and Baxa Sign Distribution Agreement Nov. 10, 2005
•BAXA and CDEX Announce Strategic Alignment Nov. 2, 2005
•CDEX’s ValiMed Unit Selected to Validate Controlled Substance Returns Oct. 13, 2005
•Maricopa Medical Center Selects CDEX’s ValiMed Technology for End Product Testing Oct. 12, 2005
•CDEX Announces Implementation and Acceptance of its ValiMed Patient Safety Solution Sept. 29, 2005
•CDEX Announces New Chief Operations Officer Sept. 19, 2005
•CDEX Begins Trading on OTCBB April 14, 2005
•University of Utah Health Sciences Center Addresses Narcotics Diversion Jan. 26, 2005
•CDEX Announces Dallas Children's Medical Center Acceptance of ValiMed Impaired Clinician Solution Jan. 14, 2005
•CDEX Announces New Vice President of Business Operations Jan. 3, 2005
•CDEX Announces Land Mine Contract with US Army June 3, 2002
•CDEX Announces Independent Verification Testing of Explosive Detection Technology May 21, 2002
•CDEX-Inc. Issues Test Reports on the EM-1 Sept. 5, 2001
Apparently the "Great Censor" on the other board doesn't feel I should post the addy to the True CDEX Longs board.
Hmmm. He's not being very kosher.
Let's see him delete it from this board.
http://ragingbull.lycos.com/mboard/viewclub.cgi?board=CLB01212
pCf
Hi Inet. I have asked a couple of times, and get no response. The (old) was added when the other board got a new moderator. Hmmmmmmmmmm! No favorites here. LOL
I know many longs who have told me that they wont post on that board with the current moderator. Not much I can do. Sorry, I have tried.
Viking why don't you get that CDEX (old) off and change it to
something else.
Did Matt stick you with the old when his buddies started their bashing board?
That board is a defensive board,you can't post intelligent stuff there, without it being torn apart just for spite. And if the joker comes back, one can not post without ridiculous censorship.
You can't expect the bashers to disappear forever,from the other I hub board it's not in their makeup. They'll probably be around at $10.00 PS, saying it is not happening.LOL
There is certainly nothing old about CDEX.
Suggestion, Make it the CEXI(CDEX) board
CDEX and BAXA Sign Distribution Agreement (HUGE NEWS)
11/10/2005 9:00:05 AM
ROCKVILLE, Md., Nov 10, 2005 (BUSINESS WIRE) -- CDEX Inc. (CEXI), developer of the ValiMed(TM) Medication Validation System and other innovative substance detection and verification systems, announces a strategic distribution agreement with Baxa Corporation, a leader in developing systems for preparing, handling, packaging, and administering liquid medications. Baxa will be the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
The ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patent-pending technology identifies the medication and strengths to validate compounded doses of high risk medications prior to dispensing. The ValiMed device verifies medications in seconds and provides an added level of safety in the medication dispensing process. The ValiMed System also validates narcotic returns.
"The ValiMed sales required under the Baxa contract, coupled with existing sales and rentals, will solidify the CDEX presence in the medical market and more completely validate our technology for other markets," said Malcolm Philips, CDEX CEO and Chairman. "With Baxa's award-winning customer service and sales teams, we have moved toward that goal in the medical marketplace."
The agreement calls for purchase of a fixed number of ValiMed units by Baxa for two years, as well as goals that must be met in order to maintain the Baxa exclusive distribution rights.
"The ValiMed System fits with Baxa Corporation's mission to offer our customers innovative fluid medication devices that improve operations and increase medication safety. ValiMed is a great addition to our product line," said Greg Baldwin, Baxa Chairman and CEO.
CDEX's mission is to develop innovative technologies that assist in solving real world problems, then work with industry leaders to bring those products to market. For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternative-site pharmacies. Privately held, Baxa Corporation has subsidiaries and offices in Canada, the United Kingdom and Denmark, and distribution partners worldwide. Further information is available at www.baxa.com.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc., Rockville
Brad Wills, 301-346-7398
bwills@wills-pr.com
or
Baxa
Marian Robinson, 303-617-2157
marian.robinson@baxa.com
Copyright Business Wire 2005
CDEX's ValiMed......
Michigan Hospital Tests Intravenous Drug Technology
By Christina Orlovsky, senior staff writer
The prevention of medication errors has always been a concern of pharmacists, lab technicians, nurses and physicians. Several new technologies, including bar coding and robotic pharmacies, have helped reduce the risk of error occurring with oral medications, but not much has been done to improve the safety of intravenous drugs—until now. Pharmacists at the University of Michigan’s C.S. Mott Children’s Hospital, in Ann Arbor, Michigan, are piloting a new technology aimed at verifying the identity and concentration of high-risk IV medications.
The ValiMed System, created by ValiMed, Inc., flashes an ultraviolet (UV) light into one-milliliter samples of medication. Each medication has a unique “fingerprint,” called a fluorescence signature, which can be detected in 30 seconds by the UV light, explained Jim Stevenson, Pharm.D., the director of pharmacy services for the University of Michigan Health System. The pharmacists compare the signature with the prescribed concentration before sending the drug out to the patient.
Originally developed to detect explosives, the ValiMed System made its foray into health care in three hospitals that use the technology to test narcotic drug returns in the operating room. C.S. Mott Children’s Hospital is the first facility to use the ValiMed System for this intravenous drug purpose.
“We were looking for a way to make the medication system safer because we know that occasionally, even with experienced pharmacists and technicians, human error can make it past the checks and practices of the hospital pharmacy. Particularly with high-risk intravenous drugs, we wanted to eliminate that human error,” Stevenson said. “When I discovered that the ValiMed System was being used to detect narcotics, I thought, why couldn’t it be used to test high-risk drugs as well?”
Stevenson worked with ValiMed, Inc., to develop the capability and decided the system would work well in the pharmacy setting. In June, the hospital began creating signatures for the top 10 high-risk medications, as determined by the pharmacy staff and a host of published studies. Among these medications are insulin, blood thinners such as heparin, painkillers like morphine and the antibiotic vancomycin. According to Stevenson, all of the medications can produce toxic effects if administered incorrectly.
While the testing of the medications takes place in the pharmacy, the ValiMed System also has an enormous impact on the nursing staff.
“From a nurse’s perspective, when an error happens in the pharmacy with intravenous drugs, there is no way for a nurse to detect and prevent that error because they are dealing with clear liquids. Nurses have to trust that the drug that’s in the bag and its concentration are correct, and they have no way to head it off if it’s not,” Stevenson explained. “This system gives them some added peace of mind and another layer of security to make sure their patient is getting the right drug and concentration.”
For more information, visit the ValiMed Web site.
Viking: delete every post of his, or he will contaminate this board also.
He's the only one seriously talking scam, liars, and bad management,why give him the floor,while aggravating everyone else.
He can delete at will on his board,you should reciprocate.
This can be a much livlier board now,since people will stop throwing up on the other board.
I put this URL on his board last night, but it didn't survive.
TO all: FWIW
From what I've read and researched..I think CDEX is now part of a VERY well run organization. They are involved in many areas of the healthcare system...They have very deep pockets and IMOP see a very bright future for CDEX.
IMOP..This should validate CDEX in the investment community.
TX and I feel better about our investment than we have ever felt...IF we could we would average down..but that's not an option for us at this time.
Hats off to MP and team!!!
Godspeed to all LONGS!!!
Baxa invests $1.5M in CDEX!
http://denver.bizjournals.com/denver/stories/2005/10/31/daily40.html?jst=b_ln_hl
Baxa Corp. has invested $1.5 million in CDEX Inc., and earned a seat on its board, the companies announced Wednesday.
The equity investment by the Denver-based Baxa Corp. also allows for an additional $1 million investment in CDEX (OTCBB: CEXI) over the next nine months. The world-wide privately held company manufactures medical devices and systems for preparing, handling, packing and administering liquid medications.
"This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market," said Greg Baldwin, Baxa's chairman and CEO.
CDEX is a development company that focuses on using chemical detection and validation technology. Currently the company is working with homeland security in identifying substances like illegal drugs and explosives and validating substances to prevent counterfeit or sub-par prescription medications. They are based in Rockville, Md. with its research and development laboratory in Tucson, Ariz.
Baxa Press Releases...
This tells us more about the company we are dealing with..
http://www.emediawire.com/releases/2005/5/prweb239166.php
* New batch syringe filler from Baxa Corporation takes a manual system and automates it, helping eliminate touch contamination. 2003-06-23
* Baxa Corporation Introduces PhaSeal®, The Only Closed System For Safe Handling of Hazardous Drugs 2003-06-26
* Baxa Corporation Announces Recent Chairman and President Promotions Within Its Leadership Team 2003-06-27
* Baxa Corporation Completes Relocation to New US Headquarters 2003-07-08
* MD Anderson and PhaSeal®: A Leader in Science Leads Adoption of New Closed System Technology For Safe Handling of Hazardous Drugs 2003-07-31
* Premier Awards Group Purchasing Agreement for Baxa Compounders 2003-09-20
* Healthcare Workers At Risk: Researchers at Utah's Huntsman Cancer Institute Demonstrate Biological Uptake of Chemotherapy Drugs. 2003-11-20
* Baxa Corporation Sponsors Symposium to Discuss Environmental Exposure and Biological Uptake of Antineoplastics at December ASHP in New Orleans 2003-11-28
* Baxa Corporation Introduces Abacus TPN Calculation Software -- for order entry and total parenteral nutrition calculation. 2003-12-08
* The future of Syringe Infusion: What's New in an Old Application? A Manufacturer's Q&A. 2004-01-11
* Baxa Introduces New Information-Based Web Site for Pharmacy Fluid-Handling and Safe Practice 2004-01-28
* Baxa Corporation sponsors best practices sessions at the National Home Infusion Association's (NHIA) annual conference on infusion safety, quality management, patient education and effective mentoring 2004-03-03
* Baxa Praises NIOSH for Alert on Preventing Occupational Exposure to Hazardous Drugs 2004-03-29
* Baxa to Sponsor Miami Symposium on Environmental Exposure and Biological Uptake of Antineoplastics 2004-04-19
* Baxa Corporation Recertified to ISO 13485 and EN46001 2004-04-30
* Baxa to Sponsor Los Angeles Symposium on Environmental Exposure and Biological Uptake of Antineoplastics 2004-05-12
* Baxa to Feature the PhaSeal(r) Closed System For Safe Handling of Hazardous Drugs at ASCO Annual Meeting in New Orleans June 5-8, 2004 2004-05-26
* Baxa Corporation Completes Six Sigma Training for Problem-Solving and Process Improvement 2004-06-11
* Baxa to Feature the PhaSeal(r) Closed System For Safe Handling of Hazardous Drugs at ASHP Summer Meeting in Las Vegas, NV 2004-06-21
* Baxa Exacta-Med® Dispensers: the World's First Dispenser Designed Specifically for Safe Delivery of Oral Medications is Now Available for Home Use in the UK 2004-07-28
* Expert Sources and Information On Hazardous Drug Handling Are Now Available for Media Access at Expert411.com 2004-07-29
* Baxa to Feature Exacta-Med® and PhaSeal® Systems For Safe Handling and Administration of Fluid Drugs at the Pharmaceutical Marketing Congress in Philadelphia 2004-09-27
* Brian Baldwin, Baxa Corporation Founder, Recognized as Medical Device Industry Pioneer 2004-09-17
* Baxa Names Jim Osgood as Vice President of Product Planning, Research and Development 2004-09-22
* Baxa Corporation Introduces ShrinkSafe® Paralytic Identification Bands for High-Alert Medications 2004-09-23
* NIOSH Publishes Alert On Preventing Occupational Exposure to Hazardous Drugs 2004-09-24
* Nursing Perspective On Hazardous Drug Handling Publishes in the Online Journal of Issues in Nursing 2004-10-23
* Baxa Launches CyTwo-Fer™ Needle - Unique Dual-Purpose Device for Safe Reconstitution of Hazardous Drugs 2004-11-03
* Baxa Sponsors Exhibitor’s Theatre on Avoiding Costly Mistakes in Complying with the Requirements of USP 797 2004-12-02
* Baxa Sponsors Exhibitor’s Theatre on Reducing Environmental Exposure to Hazardous Drugs at ASHP Mid-Year Meeting 2004-12-01
* Baxa Corporation Honors Texas Children’s Hospital in Houston with 2004 Best Practices Award 2004-12-09
* Baxa Introduces New Amber Oral Dispenser Packaging for Ward and Bedside Applications 2005-03-07
* "Understanding USP 797" and "Environmental Controls for Sterile Compounding" Technical Papers are Now Posted on PublicRelationsNewsroom.com In Light of the Continued Regulatory Focus on Hazardous Drug Handling in the Workplace 2005-01-30
* Baxa Corporation Expands Headquarters Facilities 2005-02-27
* Cleanrooms: A Question & Answer Document from Baxa Corporation is Now Posted on PublicRelationsNewsroom.com for Media and Professional Access In Light of the Continued Regulatory Focus on Hazardous Drug Handling in the Workplace 2005-02-27
* Baxa Introduces Four New Microfuse Infusion System Administration Sets 2005-03-18
* Baxa Corporation Celebrates 30 Years of Product Safety and Innovation for Hospital Pharmacies 2005-03-24
* Baxa CEO Greg Baldwin Joins Healthprolink Board of Directors 2005-03-30
* Baxa CEO Greg Baldwin Is Now Profiled at the Expert Information for Journalists Website and Available to Address Selected Business Topics 2005-04-02
* Baxa Features Exacta-Med® And PhaSeal® Systems For Safe Handling And Administration Of Fluid Drugs At Interphex 2005 2005-04-26
* Baxa Corporation Introduces New PhaSeal® System Component For Accessing Needleless Connectors 2005-05-02
* Baxa Corporation Honored with Two American Inhouse Design Awards in The National 2005 Competition Sponsored by Graphic Design USA 2005-05-07
* Baxa Corporation Awarded Colorado Governor’s Award For Excellence In Exporting 2005-05-16
* Family Business Experts Credits Family Business Synergy As Key To Baxa Corporation’s Success 2005-05-23
* Baxa Corporation Receives Small Business Exporter Of The Year Award 2005-05-30
* Baxa Corporation Announces Direct Sales And Marketing Effort In Canada Beginning June 1 2005-05-31
* Baxa Sponsors Team In Courage Classic Fundraiser For The Children’s Hospital 2005-06-03
* Baxa Corporation Awarded Best Sales Team in 2005 American Business Awards 2005-06-10
* Baxa Corporation’s Brian Baldwin Selected as Finalist for Ernst & Young 2005 Entrepreneur of The Year® Awards 2005-06-16
* Baxa Corporation’s Brian Baldwin Wins Ernst & Young 2005 Entrepreneur Of The Year® Award 2005-06-26
* Baxa Corporation’s Jeff Baldwin Provides Business Perspective To Denver’s 9News Regarding UK Terrorist Attacks 2005-07-16
* Baxa Corporation’s CEO Greg Baldwin Tours Gregg Moss of 9News Through The Company’s Sterile Medical Device Manufacturing Facilities on 'Where In The Town Is Gregg Moss' 2005-07-24
* Baxa Corporation Announces Compliance To The European Directive On Waste Electrical And Electronic Equipment 2005-08-17
* Baxa Corporation Named as Colorado Top Company Finalist 2005-08-27
* Nutrition Therapy and Continuous Infusion Case Studies From Baxa Corporation Now Available for Media Access 2005-09-02
* Exacta-Med® Oral Dispensers Eliminate Wrong-Route Errors And Inappropriate Clinical Line Connections 2005-09-02
* Baxa Repeater™ Pump Validated in Hydrogen Peroxide Vapour Sterilisation Tests 2005-09-08
* Baxa Corporation Honored as Colorado Top Company 2005-09-10
* Baxa Introduces New Oral and Enteral Liquid Dispensers with Purple Plungers to Increase Patient Safety 2005-09-13
* Baxa Corporation Receives Design Award from Art Directors Club of Denver 2005-10-03
* Process Changes at Lucile Packard Children’s Hospital Result in Safer and More Efficient Nutrition Compounding 2005-10-31
Why is that OT? Diddy, sandollar, crow talk about all kinds of things on your board, and you never say a word about OT to them. Yet thge shareholders of CDEX don't have the same rights? It is obvious that you are favoring the non shareholders!
Viking65, do you know what O/T stands for?
INET is says in the paragraph below that BAXA will be offered a seat on the CDEX board of directors. They are obviously linked very deeply with CDEX. With BAXA, CDEX has all there connections to approx. 4,000 hospitals. BAXA is a very pivital key to the future success of CDEX. It would seem obvious to any CDEX shareholder that wants to see CDEX succeed, that they would be interested in information about BAXA. To keep that information off the CDEX message board, and let the non shareholders post endlessly about Loch Harris (a dead issue) is not fair and balanced. As Loch Harris has nothing to do with the future of CDEX.
Englewood, CO and Rockville, MD – November 2, 2005 – Baxa Corporation and CDEX Inc. (OTCBB: CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a "seat on the CDEX Board of Directors".
Viking65, As moderator of this board I would like to ask you to intercede with Matt on why this post was deleted from the CEXI board. Morovan has it in his head that posters can not talk about Baxa.
These are my words,Viking For what they are worth!
This post was deleted with 13 minutes to go.
Are these Investor hub boards becoming a joke?
message 8360990 is a deleted message!!!
lMorovan as moderator and Matt as administrator of Investorshub
The only reason anyone spams a board is to increase the appearance of value to increase share prices.
Since Baxa is a private company there is no purpose in spamming it.
The only reason Baxa is mentioned on this board is to show it's value to CDEX. By the same token Baxa's name and position in the marketplace is of great interest to future potential investors.
For instance ,until yesterday practically no one even knew of Baxa. Now we want to find out all we can about our investing saviour. The way we can all be aware of what Baxa means to us and its potential value to CDEX is to have everything that can be found be posted on these boards.
One would be selfish to find something about Baxa and not share it with the shareholders and posters.
Now morovan, we mostly all realize that this potential for success is eating at your craw,and if you insist on this boycott of our investing partner, Matt would be less than efficient as an administrator to allow you to continue.
INET that is a great post! Thanks! BAXA is a great company, and I am glad CDEX is with them. What a wonderful business connection. Certainly validates CDEX doesn't it. Not that I had a problem with that.
Posted by: INET6
The vaue of this buy in, IMO is tremendous for both parties.
CDEX does not have to design and promote ,nor seek FDA approval for injectionablle mixtures. Baxa all ready has their foot well into the door. Without a doubt even with Baxa's equipment pharmacies have at times made a bad mixture and now they have the answer. Just imagine Baxa selling their mixing apparatus to pharmaceuticals and suggesting a ValiMed unit for complete assurance.
From google
Automated Filling Systems
Collection Bags, Large-Volume Filters, Pump Accessories, Repeater™ Pump, Rapid-Fill™ Automated Syringe Filler, Robotic Filling System, Scale, Syringe Strips, Syringe Filling Fixture, Top Fill Bags, Tube Sets now add ValiMed
Multi-Ingredient Solution Compounding
Abacus™ Software, Adapters, Caps, Connectors, Dual-Chamber TPN Bags, Exacta-Mix™ 2400 and 600 Compounders, Gravity Mixing Sets, Inlets, MicroMacro™ 12 and 23 Compounders, TPN Bags, Tube Sets, Valve Sets, Vial Racks now add ValiMed
IV Administration
Administration Sets, MicroFuse® Accessories, MicroFuse Infuser, MicroFuse Extended Rate Infuser, MicroFuse Rapid Rate Infuser now add ValiMed
IV Admixture
Collection Bags, Dispensing Pins, Needles, Port Saver, Rapid-Fill Connectors and Adapters, Syringes, Syringe Filters, Tamper-Evident Seals, Tip Caps, Transfer Needles, Two-Fer™ Needles, Vent Filters, Venting Pins
Oral Liquid Delivery Systems
Adapta-Cap™ Bottle Adapters and Bottlewells, Exacta-Med® Oral Dispensers and Accessories, Enteral Syringes, Gel Bags, Kwik-Vial™ Containers and Accessories, Kwik-Vial Software, Labels, Mark-a-Dose™ Labels, Tamper-Indicating Seals, Rapid-Fill Oral Connectors, Press-In Bottle Adapters, 3-Way Oral Port Sto
IMO Baxa knew what they were doing and now CDEX's scientists can concentrate on other uses of the tech.
About BAXA Corperation-very impressive.
http://www.hpc-world.com/content_archives/Fall05/06.html
Although it is more than 25 years old, Baxa Corp. says it has just begun to deliver innovative devices for oral drug delivery systems, IV admixture and administration, and solution compounding. By Hanna Aronovich
Colorado-based Baxa Corp. plans to double in size in the next five years by maximizing its internal resources. The company says it plans to do more with less and continue as an efficient provider of healthcare technology. Baxa Corp. was founded in 1975 by Brian Baldwin and Ronald Baxa. At the time, the company explains, oral liquid medications were dosed with teaspoons or graduated cups, which often resulted in inaccurate and sometimes dangerous doses. Additionally, the use of luer syringes to deliver non-sterile oral liquid medications raised the possibility of accidental injection.
Baxa Corp. introduced the Exacta-Med® Oral Dispenser in 1975. With a special tip that does not accept a needle, Exacta-Med Dispensers were designed to provide an accurate, completely safe method for dosing oral liquid drugs. The Exacta-Med Dispenser quickly became the industry standard, and remains a key part of the Baxa Corp. product line today.
CEO Greg Baldwin says Baxa Corp. has seen growth in its three major business lines: oral drug-delivery systems, IV admixture and administration, and multi-ingredient solution compounding. Success, however, creates challenges. “We need to make sure not to get complacent, so we have organized the company to promote continued success,” he says.
Baldwin acknowledges Baxa Corp. is a smaller company compared to others in the medical device arena, and “the only reason to do business with us rather than the larger companies is because our products are innovative,” he says. “We add value and solve problems better than the competition. We work hard to get to know our customers, and that translates into market knowledge and innovative solutions. Our customers challenge us to do more.”
Baldwin says Baxa Corp. works with approximately 4,000 hospitals – primarily pediatric, tertiary care and teaching hospitals. The United States represents more than 50 percent of the worldwide medical device marketplace, and Baldwin says approximately 80 percent of Baxa Corp’.s sales are domestic, while the remaining 20 percent are international sales. “We want to build lifetime relationships with companies around the world,” he stresses. “We're not just selling a product and moving on. We bring a system into a hospital and are there to meet their needs for the long haul. That's a key component to our success.”
Baxa Corp. compensates salespeople not simply for completing a sale, but for maintaining relationships. Sales representatives help customers determine exactly what medical devices they need, and guide them away from products they don't. “They take a real interest in our customers, and we reinforce that message in our training.”
Baxa Corp. identifies its customers' problems and works closely to develop solutions. Customer task forces are one way Baxa Corp. determines what products the market needs. For example, in 2003, Baxa Corp. developed the Rapid-FillTM Automated Syringe Filler, the first system designed to automate sterile batch filling in the pharmacy. Automating the process of filling, capping and labeling sterile syringes minimizes the potential for contamination and reduces pharmacy overhead. Additionally, the Rapid-Fill system increases efficiency and cost-effectiveness by filling up to 1,000 syringes an hour.
Baldwin says Baxa Corp.'s flagship product is the Exacta-MixTM 2400 Compounder, which allows pharmacies to mix up to 24 discrete ingredients into an IV nutritional solution. The companion AbacusTM Software system, a Windows-based order entry and calculation program, processes the specific prescription for use with the Exacta-Mix and other compounders.
Introduced in March 2002, Baldwin says Baxa Corp. went from the No. 2 player to the No. 1 player in the market because of the Exacta-Mix and Abacus Software systems. “About 25 percent of the tertiary care and acute care hospitals use our system, and we are thrilled about that,” he notes.
Baldwin also points to the PhaSeal® products, a closed system that allows for the safe handling of hazardous drugs. He says this product makes up more than 10 percent of Baxa Corp.'s sales. Training and operational excellence are key components to Baxa Corp.'s innovation. Baxa Corp. holds GMP training sessions, so every person in the organization understands the company's responsibilities. Baldwin says all new employees undergo a three-day, intensive new-employee orientation program, which reviews various topics depending on the employee's position.
Management and supervisory training is also a company priority, and Baldwin says managers attend several courses throughout the year to review topics in good management. The company organizes small peer groups so employees can review training topics in greater depth, share personal experiences and work together to solve problems.
Successful Endeavors
In 2003, Baxa Corp. opened a new, 93,000-square-foot facility with an 8,000-square-foot ISO Class V cleanroom. Baldwin says the upgrade allowed Baxa to expand considerably. “In 2003, we grew 24.9 percent,” he notes. “Last year, we grew 29 percent, and this year, we're on track to see a 25 percent increase in growth.”
From its initiatives, Baxa Corp. has nearly achieved its long-time goal of earning $100 million in sales. The company plans to double this figure in the next five years.
“We've been around for 30 years, and we're doing a lot of soul searching,” Baldwin says. “My father, Brian Baldwin, is the founder and vice chair of the company and Jeff Baldwin is my brother and the COO. Between the three of us, we decided that the business has only just begun, and we're focusing on bringing more processes into the 21st century of technology.” HPC
Businesswire link and article about BAXA & CDEX. The news is everywhere.
Baxa and CDEX Announce Strategic Alignment
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051102005...
ENGLEWOOD, Colo. & ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 2, 2005--Baxa Corporation and CDEX Inc. (OTCBB:CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a seat on the CDEX Board of Directors. (For additional details, see CDEX's 8K filed with the SEC.)
"We are pleased that Baxa has invested in CDEX and view this decision as a first step toward strategic alignment between Baxa and CDEX," states Malcolm Philips, CDEX's Chairman and CEO. "Baxa is a well-respected name in the medical community and its investment in CDEX will facilitate faster expansion into that and other markets."
"We looked closely at CDEX and found a technological and cultural alignment with our business and values," said Greg Baldwin, Baxa's Chairman and CEO. "This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market. We welcome the opportunity to work with CDEX in the future."
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany and distribution partners worldwide. Further information is available at www.baxa.com.
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email: Marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jerry Blair at 301.881.0080 (jblair@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
BAXA Invests $1.5 Million in CDEX!
http://denver.bizjournals.com/denver/stories/2005/10/31/daily40.html?jst=b_ln_hl
Baxa invests $1.5M in CDEX
Baxa Corp. has invested $1.5 million in CDEX Inc., and earned a seat on its board, the companies announced Wednesday.
The equity investment by the Denver-based Baxa Corp. also allows for an additional $1 million investment in CDEX (OTCBB: CEXI) over the next nine months. The world-wide privately held company manufactures medical devices and systems for preparing, handling, packing and administering liquid medications.
"This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market," said Greg Baldwin, Baxa's chairman and CEO.
CDEX is a development company that focuses on using chemical detection and validation technology. Currently the company is working with homeland security in identifying substances like illegal drugs and explosives and validating substances to prevent counterfeit or sub-par prescription medications. They are based in Rockville, Md. with its research and development laboratory in Tucson, Ariz.
Baxa and CDEX Announce Strategic Alignment
11/2/2005 12:00:01 PM
ENGLEWOOD, Colo. & ROCKVILLE, Md., Nov 02, 2005 (BUSINESS WIRE) -- Baxa Corporation and CDEX Inc. (CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a seat on the CDEX Board of Directors. (For additional details, see CDEX's 8K filed with the SEC.)
"We are pleased that Baxa has invested in CDEX and view this decision as a first step toward strategic alignment between Baxa and CDEX," states Malcolm Philips, CDEX's Chairman and CEO. "Baxa is a well-respected name in the medical community and its investment in CDEX will facilitate faster expansion into that and other markets."
"We looked closely at CDEX and found a technological and cultural alignment with our business and values," said Greg Baldwin, Baxa's Chairman and CEO. "This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market. We welcome the opportunity to work with CDEX in the future."
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany and distribution partners worldwide. Further information is available at www.baxa.com.
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email: Marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jerry Blair at 301.881.0080 (jblair@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Mr. Griffin may have breached his employment agreement by not fulfilling the requirement to purchase 300,000 shares of CDEX, and CDEX may have breached its fiduciary duties by not setting up both the price and the date the purchase must be executed.
Very impressive. For the life of me I cannot figure out why we have gone nowhere in the bomb detection arena, given the comments in this video.
Will we ever know the answer?
Blackdog
Great link for Valimed! Play the video and read the story.
http://wfrv.com/seenon/local_story_299115222.html
New Machine Helps Get Right Drug Doses
Lisa Malak
Reporting
Save It Email It Print It
(CBS News) ANN ARBOR, MI I-V Medicines Don't Always Come In Kid-Sizes.. And That Means Pharmacists Have To Mix The Drugs Themselves.
But There's New Help From A Surprising Source.
Bomb-Sniffing Technology Can Get The Dosage Just Right.
Valimed/Ann Arbor, MI
Jim Stevenson Says This Blue Machine At His Pharmacy.. Provides Peace Of Mind.
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"Particularly In A Pediatric Hospital Where You've Got High- Risk Drugs And Very Small Patients."
Even The Smallest Mistake Can Be Deadly.. But Valimed Takes Human Error Out Of The Equation.
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"We Put A Small Sample Of The Product We Wanna' Test Into The Device. It Shoots Ultraviolet Light At The Sample."
The Machine Compares The Sample To What's Called The "Fingerprint" Of The Medication.
If The Dose Is Mixed Right?
"Validated."
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"This Technology Was Initially Devised To Help Detect Explosive Devices With Homeland Security."
The University Of Michigan's Children's Hospital Is The First In The Country To Use Valimed.
Phil Mapes/Father Of Heart Patient
"It's Comforting To Know That They're Taking The Extra Step."
Phil Mapes' Daughter Meggan.. Is A Heart Patient.. Who Receives Several High-Risk Medications.
Phil Mapes/Father Of Heart Patient
"Dopamine, She's On Morphine For Pain. I Don't Know What They All Are But There's A Bunch Of Different Ones, Yeah."
Making Sure She Gets The Right Medicine In Her I-V.. Is Now One Less Thing Her Parents Have To Worry About.
The Pharmacy Is Still In The Process Of Adding New Medications To The System.
Viking65, I pointed out, on the CDEX board, at least 8 errors or misleading information in the article. Not opinions of mine, but pure facts. Now, if you don't want to see them is not my fault.
lmorovan you contain errors and misleading statements.
Viking65, the article contains errors and misleading statements, even as CDEX paid for it.
Waterville Research Investments about Cdex.
http://www.watervilleresearch.com/companies/development/247-1.html
Medication Errors in the U.S.
WHOI-TV Illinois Report
Healthbeat:Valimed
October 20, 2005
Jen Christensen
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient’s chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMed™ System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMed™, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn’t show a match, the sample is retested. If the drug can’t be validated in the second attempt, it’s sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
AUDIENCE INQUIRY
For information on ValiMed™, http://www.valimed.com/
For general information on medication errors and prevention:
Agency for Healthcare Research and Quality, http://www.ahrq.gov/qual/errorsix.htm
American Society of Health-System Pharmacists, public website, http://www.safemedication.com
The Commonwealth Fund, http://www.cmwf.org
The Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/cder
Institute for Safe Medication Practices, http://www.ismp.org
National Coordinating Council for Medication Error Reporting and Prevention, http://www.nccmerp.org
Source: http://www.hoinews.com/news/features/3/1768121.html
ValiMed On another news station out of IL. Oct. 20, '05
http://www.hoinews.com/news/features/3/1768121.html
Healthbeat:Valimed
October 20, 2005
Jen Christensen
Medication Errors in the U.S.
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient’s chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMed™ System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMed™, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn’t show a match, the sample is retested. If the drug can’t be validated in the second attempt, it’s sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
AUDIENCE INQUIRY
For information on ValiMed™, http://www.valimed.com/
For general information on medication errors and prevention:
Agency for Healthcare Research and Quality, http://www.ahrq.gov/qual/errorsix.htm
American Society of Health-System Pharmacists, public website, http://www.safemedication.com
The Commonwealth Fund, http://www.cmwf.org
The Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/cder
Institute for Safe Medication Practices, http://www.ismp.org
National Coordinating Council for Medication Error Reporting and Prevention, http://www.nccmerp.org
NOW FOR NEW NEWS TODAY ON CDEX/VALIMED:HERE ARE THE LINKS.
Advanced Chemical Sensors Co.
http://www.endonurse.com/articles/5a1innov.html
Michigan Hospital Tests Intravenous Drug Technology
http://www.nursezone.com/job/DevicesandTechnology.asp?articleID=14097
Why was post 364 pulled? It is official information posted on the SEC website.
MP files another Form 4. More insider selling:
http://www.secform4.com/insider/viewform4.php?cik=1173738&dir=000121465905001484&form=s10135...
CDEX/VALIMED TV Channel 6 Omaha, Nebraska.
Methodist Hospital
http://www.wowt.com/news/features/2/1783826.html
Getting The Meds Right
New machine lends electronic hand
I-V medicines don't always come in kid-sizes and that means pharmacists have to mix the drugs themselves. State-of-the-art technology is helping one pharmacist get the dosage just right.
Pharmacist Jim Stevenson says a blue machine that now sits on his pharmacy's countertop provides peace of mind.
"Particularly in a pediatric hospital where you've got high-risk drugs and very small patients," he says.
Pharmacists who mix millions of doses know that even the smallest mistake can be deadly but ValiMed takes human error out of the equation.
Stevenson says, "We put a small sample of the product we want to test into the device. It shoots ultraviolet light at the sample."
The machine compares the sample to what's called the "fingerprint" of that particular medication. If the dose is mixed just right, the machine's confirms that.
Stevenson says, "This technology was initially devised to help detect explosive devices with homeland security."
The University of Michigan's Children's Hospital is the first hospital in the country to use the technology to double-check medicine.
Phil Mapes' 15-year-old daughter Meggan is a heart patient who receives several high-risk medications and Phil says, "It's comforting to know that they're taking the extra step."
The pharmacy is still in the process of adding new medications to the system.
Supplemental Information
Fast Facts
· About 16 percent of Americans have experienced a prescription drug error affecting themselves or a family member.
· More than 20 percent of drug errors have serious consequences.
· Medication errors can occur at any point between the time the drug is prescribed and given to the patient.
· ValiMed is a system to verify a medication sample based on a unique fluorescent fingerprint produced by a drug.
Medication Errors in the U.S.
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient's chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMedT System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMedT, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn't show a match, the sample is retested. If the drug can't be validated in the second attempt, it's sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
Web Resources
· ValiMed
lmorovan is pulling posts left and right. God forbid you should disagree with him. "The gang that couldn't shoot straight", can openly slander people. Make false accusations, and those posts don't get removed?????? Censorship at it's worst!
New PR: CDEX's ValiMed Unit Selected to Validate Controlled Substance Returns
10/13/2005 12:30:01 PM
ROCKVILLE, Md., Oct 13, 2005 (BUSINESS WIRE) -- CDEX Inc. (CEXI) announces that its ValiMed Impaired Clinician Solution to validate narcotic returns from an operating room suite has been selected for use by a major academic medical center in the Chicago area. ValiMed provides a simple and effective way to address the Joint Commission on Accreditation of Healthcare Organizations' standards requiring that all narcotic waste be validated by a pharmacist before disposal.
"The ValiMed system comprises three components: the instrument, a proprietary library of chemical 'fingerprints,' and process automation software. The reporting capabilities of the system can help healthcare organizations document compliance with JCAHO standards for controlled substances," said Malcolm Philips, CDEX's CEO and Chairman of the Board. "We are excited and honored by the growing number of major medical facilities that are selecting the ValiMed patent pending technology to assist them and we look forward to expanding relationships with each of them in the future."
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc.
Jim Griffin or Jerry Blair
301-881-0080
cdexmanagement@cdex-inc.com
NEWS:Maricopa Medical Center Selects CDEX's ValiMed Technology for End Product Testing
Wednesday October 12, 1:00 pm ET
ROCKVILLE, Md. & PHOENIX--(BUSINESS WIRE)--Oct. 12, 2005--CDEX Inc. (OTCBB:CEXI - News) announces that Maricopa Medical Center in Phoenix, Arizona, has selected the CDEX ValiMed Patient Safety Solution to do end product testing of compounded IV medications in its pharmacy department.
ADVERTISEMENT
"We are pleased that Maricopa Medical Center has selected the CDEX ValiMed unit as a tool for end product testing," said Malcolm Philips, CEO and Chairman of the Board for CDEX. "The Maricopa Medical Center offers a great venue to continue to improve our technology. Our list of nationally recognized clients who are using ValiMed continues to grow."
The ValiMed Patient Safety Solution uses light energy and a library of unique spectral fingerprints to validate IV drugs in solution. The device can validate that the correct drug and correct dose has been added to the medication during the compounding process.
About MIHS:
Maricopa Integrated Health System is headquartered in Phoenix. The cornerstone of the system is Maricopa Medical Center (MMC), a major teaching hospital with a history dating back more than 100 years. Best known for its critical care services, the hospital offers Level 1 trauma and intensive care for adults, babies and children. Two in-patient psychiatric care centers with nearly 200 beds provide services in behavioral medicine. The nation's second largest burn treatment facility, the Arizona Burn Center, located on the main hospital campus, treats more than 800 patients per year. Eleven family health care centers are located throughout the Valley, providing primary and specialty care ranging from well baby to HIV-AIDS patient services. For more information: www.mihs.org.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
CDEX Inc., Rockville
Jim Griffin, 301-881-0080
Eagle Broadband Files Lawsuit Against Internet Posters Believed to Be Engaged in Illegal Trading Activities & Stock Manipulation Schemes
Wednesday October 5, 11:30 am ET
Company to Aggressively Seek Damages and Injunctive Relief to Ban Posters from Distributing False, Fraudulent and Misleading Information Designed to Damage the Company, its Shareholders and Stock
HOUSTON--(BUSINESS WIRE)--Oct. 5, 2005-- Eagle Broadband, Inc. (AMEX:EAG - News), a leading provider of broadband, Internet protocol (IP) and communications technology and services, announced today that the company has filed a lawsuit containing claims for defamation and unfair business practices in the Superior Court of California against 25 anonymous "John Doe" defendants alleging that these defendants have distributed false, fraudulent and misleading misinformation on Internet message boards in an effort to damage Eagle's business and its shareholders, and to drive down the value of its stock in order to reap profits for themselves.
ADVERTISEMENT
The 25 "John Doe" defendants named in the lawsuit include individuals using the following Internet message board ID's: "upanddown100", "team_3339", "bubba2o", "benderanddundat", "advanced_headlines", "richwill21", and "phil_phd2003", among others. The company may add additional defendants to this lawsuit as additional evidence warrants.
The company has evidence that these posters have engaged in unlawful activities and is seeking monetary and punitive damages from these individuals and/or firms who have engaged in deliberate misinformation campaigns designed to drive down the price of the company's stock in an apparent attempt to capture illegal gains from short sales.
The fraudulent and misleading information distributed by these defendants has been posted on widely visited financial Internet message boards including Yahoo! Finance, Raging Bull and others. The information has included, but is not limited to, fraudulent statements about the financial condition and business activities of the company, erroneous information about the company's products, partners and customers, and personal attacks against the company's management, board of directors and employees. The lawsuit is designed to stop these individuals and/or firms from continuing these illegal activities as well as to seek the full measure of damages and other remedies permitted by law.
"While Eagle Broadband fully respects individuals' right to free speech, we will not tolerate deliberate misinformation campaigns that disseminate false and fraudulent statements that damage the company, our shareholders and the value of our stock," said David Micek, President and CEO of Eagle Broadband.
Micek continued, "The internal committee we previously formed to investigate improper trading activities has uncovered solid evidence of fraudulent and defamatory information being posted on various Internet sites. While we support the use of the Internet to discuss the company and its progress, we believe it is now appropriate to aggressively pursue all available regulatory and legal remedies against those engaging in these illegal schemes. Our goal is to do everything we can to put a stop to these illegal activities and seek maximum damages for the benefit of Eagle and its shareholders."
"As the company remains focused on growing the business, our internal committee and legal team will continue to closely monitor the online message boards, and we will remain extremely vigilant in our efforts to uncover and take action against any individuals or firms engaged in these illegal activities," Micek added.
OT, In the torah it's much more frequently refered to as Adonai.
Gary
O/T lmorovan, thanks
O/T INET,
In the Torah is spelled YAHVEH, from which we get Jehova.
OT lmorovan! Thank You!
This is interesting,(although IMO silly,as far as so holy is concerned)! certainly not meant offensively!
Do you know how it is spelled throughout the Torah?
O/T INET,
Some denominations, sects and cults believe that the name of God is "so holy" that it is a sin to write it down, even as He himself uses that name. For that reason they use G-d rather than the whole name, God.
Furthermore, some satanic cults and other abominable sects refuse to give God the Glory that is due to Him, and try to minimize Him by calling G-d.
OT: Viking, a question.
What is the significance of the spelling of God?
In each instance it is written as G-d.
If you know, I would appreciate an answer,I can't recall ever running across it before.
Actually if anyone knows I would appreciate clarification.
INET6
Ski Tahoe, Happy Rosh Hashanah. May the New Year bring us all good fortune.
Quiz: What year is it on the Jewish calender?
ROSH HASHANAH:
Origins
By: Amy J. Kramer
Rosh Hashanah, which literally means the head of the year, commemorates the anniversary of the creation of the world. It is celebrated on the first and second days of the seventh Hebrew month, Tishri. Depending on the solar calendar, Rosh Hashanah occurs in September or October.
Rosh Hashanah, when all living things are judged, is often referred to as the beginning of the Jewish New Year. However, the Hebrew month of Nissan, in which Passover is celebrated, is the first month of the Jewish calendar.
Rosh Hashanah is actually only one of four symbolic Jewish new year celebrations. The Talmud identifies these as:
Nisan: The Hebrew month of Passover marks the birth of the Jews as a free nation. It was also the symbolic new year day for kings.
Elul: The Hebrew month preceding Rosh Hashanah was the symbolic new year for tithing animals, an ancient form of giving tzedakah, or charity;
Shevat: The Hebrew month of the holiday, Tu Bishvat, was the symbolic new year for trees.
Tishri: The Hebrew month of Rosh Hashanah, was the symbolic anniversary of the creation of the world.
The commandment to observe Rosh Hashanah is found in the second and third books of the Torah, the five books of Moses:
In the seventh month, in the first day of the month, shall be a solemn rest unto you, a memorial proclaimed with the blast of horns, a holy convocation... and you shall bring an offering made by fire unto the Lord. Leviticus 23:24-5
--------------------------------------------------------------------------------
In the seventh month, on the first day of the month, you shall observe a holy day; you shall not work at your occupations. You shall observe it as a day when the shofar is trumpeted. Numbers 29:1
The first two days of Tishri were not called Rosh Hashanah until Talmudic times. Jewish leaders of the day may have been reluctant to promote large celebrations around a fall new year because moon festivals were common among pagan religions. Many Near Eastern religions, for example, celebrated divine coronation festivals in the Fall.
By the fourth century, B.C.E., when the Jews returned from Babylonian exile to build the second temple, Rosh Hashanah was well established. By the time of the Mishnah, the codification of Jewish oral traditon, Rosh Hashanah had developed a more serious tone. Now, having suffered the loss of the second temple, Rosh Hashanah emphisized the anniversary of creation, and of G-d as judge, dispensing mercy or justice to those who do or do not repent their sins.
The Torah refers to Rosh Hashanah as Yom Teruah, the day of sounding the shofar, the traditional ram's horn. It is also called Yom Ha'Din, the day of judgement as well as Yom Hazikaron, the day of remembering. Yom Hazikaron is a reference to the patriarch Abraham who offered his only son, Isaac, to G-d as proof of his obedience. As the result of his readiness to sacrifice Isaac, G-d caused a ram to appear and be killed instead. According to Jewish tradition, this sacrifice is believed to have occurred the first of Tishri.
Today, aside from liturgical additions and literary interpretations made by poets during the Middle Ages, the customs, traditions, mood and spirit of Rosh Hashanah remain basically unchanged.
No it doesn't disturb me at all. There are many people on the net who have many identities, I'm just not one of them.
Gary
Skitahoe I hope I didn't upset you with that insult. The CROW referred to Himanez who is moderator of that board ,but Silicon Investor says it is not moderated, but don't argue with them they will suspend you.LOL
INET, if you're referring to me, I've never gone by anything other than my name and skitahoe, I'm not Crow.
Thanks, I've added the link in SI where I am also active. It seems like LMO tries to control as many sites as he can. He must be a very busy man just keeping up with all the CDEX sites where he wants his opinionated views to predominate.
I just hope that MP isn't holding back information because he thinks whatever he does will simply result in further conflict with LMO and perhaps others. It seems like there are people like LMO involved in almost every stock, at least the majority I'm active in.
By the way, I'm Jewish, if there are others out there who are active here, Happy New Year's.
Gary
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
516
|
Created
|
05/17/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |